JP2011513419A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513419A5 JP2011513419A5 JP2010549840A JP2010549840A JP2011513419A5 JP 2011513419 A5 JP2011513419 A5 JP 2011513419A5 JP 2010549840 A JP2010549840 A JP 2010549840A JP 2010549840 A JP2010549840 A JP 2010549840A JP 2011513419 A5 JP2011513419 A5 JP 2011513419A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- substituted
- pharmaceutically acceptable
- compound
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- -1 amino, substituted amino Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000002062 proliferating effect Effects 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 4
- 150000001408 amides Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 229940127084 other anti-cancer agent Drugs 0.000 claims 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical class COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical class 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- ZGTFNNUASMWGTM-UHFFFAOYSA-N 1,3-thiazole-2-carbaldehyde Chemical compound O=CC1=NC=CS1 ZGTFNNUASMWGTM-UHFFFAOYSA-N 0.000 claims 1
- PZPNGWWKCSJKOS-UHFFFAOYSA-N 6-fluoropyridine-3-carbaldehyde Chemical compound FC1=CC=C(C=O)C=N1 PZPNGWWKCSJKOS-UHFFFAOYSA-N 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical class NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000001951 carbamoylamino group Chemical class C(N)(=O)N* 0.000 claims 1
- 125000004093 cyano group Chemical class *C#N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- DXBWJLDFSICTIH-UHFFFAOYSA-N pyrazine-2-carbaldehyde Chemical compound O=CC1=CN=CC=N1 DXBWJLDFSICTIH-UHFFFAOYSA-N 0.000 claims 1
- 150000003216 pyrazines Chemical class 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 **c(nc1Nc2n[n]c(*)c2)n[n]2c1c(*)c(*)c2* Chemical compound **c(nc1Nc2n[n]c(*)c2)n[n]2c1c(*)c(*)c2* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3417108P | 2008-03-06 | 2008-03-06 | |
| PCT/US2009/035975 WO2009111531A1 (en) | 2008-03-06 | 2009-03-04 | Pyrrolotriazine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011513419A JP2011513419A (ja) | 2011-04-28 |
| JP2011513419A5 true JP2011513419A5 (enExample) | 2012-03-15 |
Family
ID=40578742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010549840A Pending JP2011513419A (ja) | 2008-03-06 | 2009-03-04 | ピロロトリアジンキナーゼ阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8212031B2 (enExample) |
| EP (1) | EP2262806A1 (enExample) |
| JP (1) | JP2011513419A (enExample) |
| CN (1) | CN102015719A (enExample) |
| WO (1) | WO2009111531A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5592890B2 (ja) | 2008-10-08 | 2014-09-17 | ブリストル−マイヤーズ スクイブ カンパニー | ピロロトリアジンキナーゼ阻害剤 |
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| JP5889795B2 (ja) | 2009-11-05 | 2016-03-22 | ライゼン・ファーマシューティカルズ・エスアー | 新規キナーゼモジュレーター |
| PH12013502240B1 (en) | 2011-05-04 | 2018-06-27 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of protein kinase |
| KR102216606B1 (ko) | 2012-07-04 | 2021-02-17 | 리젠 파마슈티컬스 소시에떼 아노님 | 선택적 pi3k 델타 억제제 |
| US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| WO2015081783A1 (zh) * | 2013-12-06 | 2015-06-11 | 江苏奥赛康药业股份有限公司 | 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途 |
| CN111018860B (zh) * | 2018-10-10 | 2022-06-10 | 中国药科大学 | 吡咯并三嗪类化合物及其应用 |
| CN110950871B (zh) * | 2019-12-25 | 2022-05-17 | 陕西师范大学 | 2-取代-4-芳氨基吡唑并三嗪衍生物及制备抗肿瘤药物的应用 |
| CA3246424A1 (en) | 2022-04-08 | 2023-10-12 | SHY Therapeutics LLC | Compounds interacting with proteins of the RAS superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1620437B1 (en) * | 2003-04-29 | 2009-06-17 | Pfizer Limited | 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension |
| PT2041138E (pt) * | 2006-07-07 | 2014-10-07 | Bristol Myers Squibb Co | Inibidores de pirrolotriazina quinase |
| US7531539B2 (en) | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2008131050A1 (en) | 2007-04-18 | 2008-10-30 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| JP5592890B2 (ja) * | 2008-10-08 | 2014-09-17 | ブリストル−マイヤーズ スクイブ カンパニー | ピロロトリアジンキナーゼ阻害剤 |
-
2009
- 2009-03-04 WO PCT/US2009/035975 patent/WO2009111531A1/en not_active Ceased
- 2009-03-04 EP EP09716856A patent/EP2262806A1/en not_active Withdrawn
- 2009-03-04 JP JP2010549840A patent/JP2011513419A/ja active Pending
- 2009-03-04 CN CN2009801164877A patent/CN102015719A/zh active Pending
- 2009-03-04 US US12/920,511 patent/US8212031B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011513419A5 (enExample) | ||
| TWI798446B (zh) | 作為核轉運調節劑之化合物及其用途 | |
| ES2923875T3 (es) | Moduladores de la vía integrada del estrés | |
| JP2019517487A5 (enExample) | ||
| JP7182304B2 (ja) | インドリノン化合物の使用 | |
| JP2017528498A5 (enExample) | ||
| JP2019537585A (ja) | Ｅｚｈ２媒介性がんを治療するための組成物および方法 | |
| JP2014521653A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| US20110178087A1 (en) | Compositions and Their Use as Anti-Tumor Agents | |
| JP2011510056A5 (enExample) | ||
| JP2014503567A5 (enExample) | ||
| JP2007534695A5 (enExample) | ||
| JP2010524957A5 (enExample) | ||
| JP2008001718A5 (enExample) | ||
| EP4086250B1 (en) | Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same | |
| JP2020527173A5 (enExample) | ||
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| US20170081322A1 (en) | Compounds which inhibit rna polymerase, compositions including such compounds, and their use | |
| US20210000825A1 (en) | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | |
| AU2022265718A1 (en) | Deubiquitinase-targeting chimeras and related methods | |
| US20200268728A1 (en) | Drug targeting cancer stem cell | |
| JP6422936B2 (ja) | ５−ブロモ−インジルビン | |
| CN108601785A (zh) | 嘧啶并哒嗪酮在治疗癌症中的用途 |